Sarah King, NP
Nurse Practitioner · Austin, TXNPI 1386140150
Payments from drug & device makers
Across 120 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$402
- Abbott$305
- Novo Nordisk$198
- Dexcom, Inc.$149
- Medtronic$135
- Amgen$102
- plus $950 from 23 others
What the payments were for
- Food & beverage$2,23099%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $402 |
| Abbott | 17 | $305 |
| Novo Nordisk | 12 | $198 |
| Dexcom, Inc. | 7 | $149 |
| Medtronic | 8 | $135 |
| Amgen | 5 | $102 |
| Insulet Corporation | 5 | $95 |
| Bayer | 5 | $91 |
| Corcept Therapeutics | 4 | $84 |
| Cequr Corporation | 2 | $59 |
| AstraZeneca | 3 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Radius Health, Inc. | 2 | $55 |
| AbbVie | 3 | $53 |
| IBSA Pharma Inc. | 3 | $52 |
| Tandem Diabetes Care, Inc. | 3 | $48 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Mannkind Corporation | 2 | $41 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Microtransponder, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $23 |
| Pfizer | 1 | $22 |
| Novartis | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Alvogen Inc | 1 | $17 |
| Halozyme Inc | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$2,242 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 364 | $487,863 |
| OzempicSemaglutide | 236 | $306,653 |
| TrulicityDulaglutide | 117 | $173,152 |
| JardianceEmpagliflozin | 103 | $131,324 |
| FarxigaDapagliflozin Propanediol | 69 | $66,413 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 84 | $52,058 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 34 | $49,833 |
| Teriparatide | 17 | $33,796 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $32,901 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $31,823 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $31,108 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $28,540 |
| RybelsusSemaglutide | 16 | $27,687 |
| Humalog Kwikpen U-100Insulin Lispro | 65 | $23,179 |
| Novolog FlexpenInsulin Aspart | 42 | $21,524 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $402 | $666,280496 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $198 | $341,369280 claims |
| AstraZenecaFarxiga | $58 | $66,41369 claims |
| Alvogen IncTeriparatide | $17 | $33,79617 claims |
| AbbVieSynthroid | $53 | $4,02460 claims |
| Sanofi-aventis U.S. LLCLantus | $57 | $2,61320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Austin
- Cecilia DavisAustin$262K
- Patricia MedinaAustin$64K
- Jordan HarborthAustin$27K
- Natasha GibbsAustin$20K
- Kaycee FrederickAustin$17K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.